<DOC>
	<DOCNO>NCT01740401</DOCNO>
	<brief_summary>The purpose study see whether combination low-dose Cyclophosphamide Anti-CTLA4 ( Ipilimumab ) stop tumor growth patient advanced skin cancer . The investigator expect see increase response rate combination Anti-CTLA-4 alone estimate response rate approximately 20 % propose population .</brief_summary>
	<brief_title>CTLA-4 Blockade Low Dose Cyclophosphamide Patients With Advanced Malignant Melanoma</brief_title>
	<detailed_description>The transient removal CTLA-4-mediated inhibition ( CTLA-4 blockade ) induce effective anti-tumor immunity . Efficacy CTLA-4 blockade single agent show melanoma 53 . It hypothesize anti-CTLA-4 antibody might deplete Treg cell 54 , induce autoimmunity . However , patient receive Ipilimumab show decrease Treg number function peripheral blood 55 . This trial answer question combination Anti-CTLA 4 ( follow well establish regimen Ipilimumab ) Cyclophosphamide ( give immunomodulatory dos ) result antitumor activity patient metastatic melanoma due synergistic immunomodulating effect overcome tolerance .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Men &amp; woman , age ≥18 2 . Willing/able give write informed consent . 3 . Histologic diagnosis unresectable AJCC Stage III/IV malignant melanoma 4 . At least 2wks must elapse since last chemotherapy , immunotherapy , hormonal therapy , radiotherapy major surgery &amp; begin protocol therapy . At least 6wks nitrosoureas , mitomycin C , &amp; liposomal doxorubicin 5 . Toxicity related prior therapy must either return ≤ grade 1 baseline . 6 . Two punch tumor biopsy Screening Wk12 ( 4mm diameter ) must provide immune analysis/staining patient accessible disease . Biopsies optional Maintenance Period.Site tumor biopsy s/n site measurable disease . Minimum 5 1st 10 patient stage I protocol must biopsy accessible disease . 7 . Patients must measurable disease define @ least 1 lesion accurately measure @ least 1 dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . 8 . Required value initial laboratory test : 1 . WBC ≥ 2000/uL 2 . ANC ≥ 1000/uL 3 . Platelets ≥ 50 x 103/uL 4 . Hemoglobin ≥ 9.5 g/dL 5 . Creatinine ≤ 3.0 x ULN 6 . AST/ALT ≤ 2.5 x ULN patient without liver metastasis , ≤ 5 x ULN patient liver metastasis 7 . Bilirubin ≤ 3.0 x ULN , ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL ) 9 . Life expectancy least 4mos 10 . Patients w/stable , treated central nervous system ( CNS ) metastasis eligible 11 . ECOG Performance Status Score 01 12 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study &amp; 26wks last dose investigational product , manner risk pregnancy minimize . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define : Amenorrhea ≥ 12 consecutive month w/o another cause , For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum folliclestimulating hormone ( FSH ) level ≥ 35 mIU/mL . Women use oral contraceptive , hormonal contraceptive ( vaginal products/skin patches/implanted/injectable product ) , mechanical product intrauterine device barrier method ( diaphragm/condoms/ spermicide ) prevent pregnancy , practice abstinence partner sterile ( eg vasectomy ) consider childbearing potential . WOCBP must negative urine serum pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) w/in 72hrs start ipilimumab . 13 . Men father potential must use adequate method contraception avoid conception throughout study [ 26wks last dose investigational product ] way risk pregnancy minimize . 1 . Any malignancy patient diseasefree less 5yrs , exception adequately treat &amp; cure basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix . 2 . Autoimmune disease : Patients history inflammatory bowel disease , include ulcerative colitis Crohn 's Disease , exclude study , patient history symptomatic disease ( eg rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ eg Wegener 's Granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( eg GuillainBarre Syndrome Myasthenia Gravis ) . 3 . Any underlying medical psychiatric condition , opinion investigator make administration ipilimumab hazardous obscure interpretation AEs , like condition associate frequent diarrhea . 4 . Uncontrolled significant cardiovascular disease 5 . Any nononcology vaccine therapy use prevention infectious disease ( 1mo before/after dose ipilimumab ) . 6 . History prior treatment ipilimumab prior CD137 agonist CTLA 4 inhibitor agonist . 7 . Concomitant therapy following : IL 2 , interferon , nonstudy immunotherapy regimen ; immunosuppressive agent ; investigation therapy ; chronic use systemic corticosteroid ( &gt; 60mg prednisone/day ) . 8 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( eg infectious ) illness . 9 . Women childbearing potential ( WOCBP ) , define : 1. unwilling/unable use acceptable method contraception avoid pregnancy entire study period least 26wks cessation study drug , 2. positive pregnancy test baseline , 3. pregnant breastfeeding . 10 . Persons reproductive potential unwilling use adequate method contraception throughout treatment &amp; least 26wks ipilimumab stop .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Advanced Malignant Melanoma</keyword>
	<keyword>Anti CTLA4 Blockade</keyword>
	<keyword>Progression Free Survival</keyword>
	<keyword>Interventional Therapy</keyword>
	<keyword>Phase II Clinical Trial</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>T Cell Activation</keyword>
</DOC>